Veracyte, Inc. (VCYT)Stock Price & Financial Statements
AboutVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Show more
- Revenue $517M +16.0%
- EBITDA $58M +45.9%
- Net Income $66M +174.9%
- EPS (Diluted) 0.82 +164.5%
- Gross Margin 70.1% +4.8%
- EBITDA Margin 11.17% +25.8%
- Operating Margin 11.17% +208.5%
- Net Margin 12.83% +136.9%
- ROE 5.34% +145.5%
- ROIC 4.39% +231.4%
- Debt/Equity 0.03 -29.8%
- Interest Coverage -
Key Insights
Based on financial data analysisStrengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 24.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 34.5%
Weaknesses
- ✗Weak 3Y average ROE of 0.2%
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y26.44%
5Y34.5%
3Y20.37%
TTM16.01%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM174.89%
EPS CAGR
10Y-
5Y-
3Y-
TTM171.83%
ROCE
10Y Avg-13.26%
5Y Avg-3.25%
3Y Avg-0.69%
Latest4.5%
Peer Comparison
Diagnostics and Omics Tools| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
VCYTVeracyte, Inc. | 2.88B | 36.27 | 44.23 | 16.01% | 12.83% | 5.07% | 4.4% | 0.03 |
 ASBPWAspire Biopharma Holdings, Inc. | 178.9K | 0.02 | -0.01 | -16351.77% | ||||
 VRAXVirax Biolabs Group Limited | 1.55M | 0.21 | -0.11 | -95.95% | -78.62% | -234.24% | 0.07 | |
 CDIOCardio Diagnostics Holdings, Inc. | 141.46M | 5.26 | -0.57 | 104.45% | -415.16% | -80.38% | 0.10 | |
 AIMDAinos, Inc. | 7.24M | 1.51 | -0.97 | -83.02% | -132.32% | -148.9% | 0.77 | |
 IMDXInsight Molecular Diagnostics Inc. | 95.47M | 5.47 | -1.17 | 25.15% | -13.81% | -14.81% | ||
 SEERSeer, Inc. | 103.2M | 1.85 | -1.33 | -8.13% | -486.02% | -29.19% | 0.08 | |
 ASBPAspire Biopharma Holdings, Inc. | 62.88M | 1.32 | -5.08 | -16351.99% |
Compare VCYT vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 65.08M | 71.95M | 92.01M | 120.37M | 117.48M | 219.51M | 296.54M | 361.05M | 445.76M | 517.14M |
| Revenue Growth % | 31.48% | 10.55% | 27.87% | 30.82% | -2.4% | 86.85% | 35.09% | 21.76% | 23.46% | 16.01% |
| Cost of Goods Sold | 25.46M | 28.2M | 33.08M | 36.52M | 41.45M | 74.4M | 101.58M | 112.9M | 147.62M | 154.61M |
| COGS % of Revenue | 39.12% | 39.19% | 35.95% | 30.34% | 35.29% | 33.89% | 34.26% | 31.27% | 33.12% | 29.9% |
| Gross Profit | 39.62M | 43.76M | 58.93M | 83.84M | 76.03M | 145.11M | 194.95M | 248.15M | 298.14M | 362.53M |
| Gross Margin % | 60.88% | 60.81% | 64.05% | 69.66% | 64.71% | 66.11% | 65.74% | 68.73% | 66.88% | 70.1% |
| Gross Profit Growth % | 41.48% | 10.44% | 34.67% | 42.28% | -9.32% | 90.87% | 34.35% | 27.29% | 20.15% | 21.6% |
| Operating Expenses | 68.43M | 70.3M | 81.16M | 98.97M | 111.42M | 227.02M | 236.03M | 333.94M | 282M | 281.76M |
| OpEx % of Revenue | 105.13% | 97.7% | 88.21% | 82.22% | 94.84% | 103.42% | 79.6% | 92.49% | 63.26% | 54.48% |
| Selling, General & Admin | 52.03M | 55.35M | 65.28M | 82.72M | 89.12M | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| SG&A % of Revenue | 79.95% | 76.92% | 70.95% | 68.72% | 75.86% | 82.54% | 58.7% | 51.03% | 46.22% | 40.79% |
| Research & Development | 15.32M | 13.88M | 14.82M | 14.85M | 17.2M | 29.84M | 40.6M | 57.3M | 69.29M | 70.81M |
| R&D % of Revenue | 23.54% | 19.29% | 16.11% | 12.34% | 14.64% | 13.59% | 13.69% | 15.87% | 15.54% | 13.69% |
| Other Operating Expenses | 202K | 476K | 1.2M | 1.4M | 5.09M | 15.98M | 21.35M | 92.41M | 6.67M | 0 |
| Operating Income | -28.8M | -26.54M | -22.23M | -15.13M | -35.39M | -81.9M | -41.08M | -85.8M | 16.14M | 57.78M |
| Operating Margin % | -44.25% | -36.88% | -24.16% | -12.57% | -30.12% | -37.31% | -13.85% | -23.76% | 3.62% | 11.17% |
| Operating Income Growth % | 13.93% | 7.86% | 16.22% | 31.96% | -133.95% | -131.44% | 49.84% | -108.84% | 118.81% | 257.93% |
| EBITDA | -25.29M | -22.7M | -18.31M | -11.01M | -27.45M | -60.68M | -11.83M | -58.61M | 39.6M | 57.78M |
| EBITDA Margin % | -38.86% | -31.54% | -19.9% | -9.15% | -23.36% | -27.64% | -3.99% | -16.23% | 8.88% | 11.17% |
| EBITDA Growth % | 22.57% | 10.26% | 19.32% | 39.88% | -149.27% | -121.09% | 80.5% | -395.28% | 167.57% | 45.9% |
| D&A (Non-Cash Add-back) | 3.51M | 3.84M | 3.92M | 4.12M | 7.94M | 21.23M | 29.25M | 27.19M | 23.46M | 0 |
| EBIT | -28.65M | -27.6M | -21.04M | -11.92M | -34.68M | -81.41M | -36.23M | -76.6M | 25.75M | 0 |
| Net Interest Income | -2.76M | -4.94M | -1.96M | 2.35M | 365K | -106K | 1.77M | 7.33M | 11.15M | 0 |
| Interest Income | 0 | 0 | 0 | 3.02M | 594K | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 2.76M | 4.94M | 1.96M | 677K | 229K | 241K | 198K | 15K | 2K | 0 |
| Other Income/Expense | -2.56M | -4.46M | -766K | 2.53M | 480K | 254K | 4.65M | 9.18M | 9.6M | 10.42M |
| Pretax Income | -31.36M | -31M | -23M | -12.6M | -34.91M | -81.65M | -36.43M | -76.61M | 25.74M | 68.2M |
| Pretax Margin % | -48.18% | -43.09% | -25% | -10.47% | -29.71% | -37.2% | -12.28% | -21.22% | 5.78% | 13.19% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -6.09M | 133K | -2.21M | 1.61M | 1.85M |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 100% | 92.55% | 100.37% | 97.12% | 93.76% | 97.29% |
| Net Income | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M |
| Net Margin % | -48.18% | -43.09% | -25% | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | 5.42% | 12.83% |
| Net Income Growth % | 6.96% | 1.13% | 25.82% | 45.22% | -177.08% | -116.46% | 51.62% | -103.51% | 132.44% | 174.89% |
| Net Income (Continuing) | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.09 | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 |
| EPS Growth % | 16.15% | 16.51% | 31.87% | 56.45% | -144.44% | -68.18% | 54.05% | -100% | 130.39% | 164.52% |
| EPS (Basic) | -1.09 | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.32 | 0.84 |
| Diluted Shares Outstanding | 28.83M | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
| Basic Shares Outstanding | 28.83M | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 73.63M | 53.93M | 96.95M | 187.69M | 375.68M | 243.1M | 248.64M | 285.62M | 372.27M | 488.38M |
| Cash & Short-Term Investments | 59.22M | 33.89M | 78M | 159.32M | 349.36M | 177.16M | 178.85M | 216.45M | 289.44M | 412.89M |
| Cash Only | 59.22M | 33.89M | 78M | 159.32M | 349.36M | 173.2M | 154.25M | 216.45M | 239.09M | 362.58M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 3.96M | 24.61M | 0 | 50.35M | 50.31M |
| Accounts Receivable | 8.76M | 12.72M | 13.17M | 19.33M | 18.46M | 41.46M | 44.02M | 40.38M | 46.52M | 44.66M |
| Days Sales Outstanding | 49.1 | 64.51 | 52.24 | 58.61 | 57.36 | 68.94 | 54.18 | 40.82 | 38.1 | 31.52 |
| Inventory | 3.48M | 5.32M | 3.4M | 6.81M | 4.66M | 11.22M | 14.29M | 16.13M | 21.75M | 20.55M |
| Days Inventory Outstanding | 49.81 | 68.92 | 37.54 | 68.02 | 41 | 55.07 | 51.36 | 52.14 | 53.78 | 48.5 |
| Other Current Assets | 320K | 2M | 0 | 0 | 0 | -3.96M | 11.47M | 12.66M | 14.55M | 10.28M |
| Total Non-Current Assets | 27.41M | 24.74M | 23.69M | 87.53M | 81.48M | 944.72M | 907.79M | 829.28M | 927.77M | 917.64M |
| Property, Plant & Equipment | 11.48M | 9.69M | 8.94M | 17.74M | 16.83M | 31.14M | 30.86M | 30.86M | 71.14M | 58.79M |
| Fixed Asset Turnover | 5.67x | 7.43x | 10.29x | 6.78x | 6.98x | 7.05x | 9.61x | 11.70x | 6.27x | 8.80x |
| Goodwill | 1.06M | 1.06M | 1.06M | 2.73M | 2.73M | 707.9M | 695.89M | 702.98M | 745.8M | 767.15M |
| Intangible Assets | 14.13M | 13.07M | 12M | 65.02M | 59.92M | 202.73M | 174.87M | 88.59M | 102.3M | 89.15M |
| Long-Term Investments | 603K | 603K | 603K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 737K | 929K | 1.69M | 2.04M | 2M | 2.95M | 6.17M | 6.85M | 8.53M | 2.55M |
| Total Assets | 101.03M | 78.67M | 120.64M | 275.21M | 457.16M | 1.19B | 1.16B | 1.11B | 1.3B | 1.41B |
| Asset Turnover | 0.64x | 0.91x | 0.76x | 0.44x | 0.26x | 0.18x | 0.26x | 0.32x | 0.34x | 0.37x |
| Asset Growth % | 34.2% | -22.14% | 53.35% | 128.13% | 66.11% | 159.83% | -2.64% | -3.59% | 16.6% | 8.15% |
| Total Current Liabilities | 11.53M | 12.03M | 13.06M | 17.47M | 16.78M | 64.15M | 62.61M | 61.24M | 78.63M | 59.94M |
| Accounts Payable | 2.42M | 3.85M | 2.52M | 2.33M | 3.12M | 12.36M | 11.91M | 12.94M | 8.63M | 4.59M |
| Days Payables Outstanding | 34.75 | 49.88 | 27.76 | 23.27 | 27.44 | 60.64 | 42.8 | 41.84 | 21.35 | 10.84 |
| Short-Term Debt | 0 | 0 | 1.36M | 0 | 0 | 1.13M | 0 | 0 | 0 | 4.05M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 371K | 4.65M | 2.61M | 2.01M | 1.67M | 1.16M |
| Other Current Liabilities | 0 | 0 | 0 | 10.1M | 9.2M | 33.7M | 36.88M | 29.19M | 47.59M | 50.13M |
| Current Ratio | 6.38x | 4.48x | 7.42x | 10.74x | 22.39x | 3.79x | 3.97x | 4.66x | 4.73x | 8.15x |
| Quick Ratio | 6.08x | 4.04x | 7.16x | 10.35x | 22.11x | 3.61x | 3.74x | 4.40x | 4.46x | 7.81x |
| Cash Conversion Cycle | 64.17 | 83.55 | 62.01 | 103.36 | 70.92 | 63.37 | 62.75 | 51.12 | 70.53 | 69.18 |
| Total Non-Current Liabilities | 29.92M | 29.42M | 27.82M | 18.29M | 19.15M | 27.16M | 18.61M | 9.56M | 45.44M | 36.51M |
| Long-Term Debt | 24.92M | 24.94M | 23.93M | 694K | 810K | 0 | 0 | 0 | 0 | 35.6M |
| Capital Lease Obligations | 599K | 308K | 0 | 11.51M | 9.92M | 14.1M | 10.65M | 7.53M | 43.24M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 5.59M | 4.53M | 734K | 1.23M | 646K |
| Other Non-Current Liabilities | 4.4M | 4.17M | 3.9M | 6.09M | 7.59M | 7.13M | 3.43M | 1.3M | 972K | 257K |
| Total Liabilities | 41.45M | 41.44M | 40.88M | 35.76M | 35.93M | 91.31M | 81.22M | 70.8M | 124.07M | 96.44M |
| Total Debt | 25.52M | 25.25M | 25.28M | 13.61M | 12.32M | 18.85M | 14.72M | 12.63M | 50.74M | 39.65M |
| Net Debt | -33.7M | -8.64M | -52.71M | -145.71M | -337.05M | -154.34M | -139.53M | -203.82M | -188.35M | -322.92M |
| Debt / Equity | 0.43x | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 1.28x | 0.69x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -4.76x | -5.59x |
| Interest Coverage | -10.45x | -5.37x | -11.33x | -22.34x | -154.54x | -339.85x | -207.48x | -5719.67x | 8071.00x | - |
| Total Equity | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | 1.1B | 1.08B | 1.04B | 1.18B | 1.31B |
| Equity Growth % | 16.25% | -37.52% | 114.25% | 200.24% | 75.91% | 160.31% | -1.94% | -2.89% | 12.63% | 11.36% |
| Book Value per Share | 2.07 | 1.10 | 2.15 | 5.19 | 7.91 | 16.15 | 15.03 | 14.37 | 15.05 | 16.25 |
| Total Shareholders' Equity | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | 1.1B | 1.08B | 1.04B | 1.18B | 1.31B |
| Common Stock | 34K | 34K | 41K | 50K | 58K | 71K | 72K | 73K | 78K | 0 |
| Retained Earnings | -180.08M | -211.09M | -234.09M | -246.69M | -281.59M | -357.16M | -393.72M | -468.12M | -443.98M | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6.84M | -9.3M | -12.01M | 0 | 0 | -15.08M | -31.35M | -24.02M | -36.09M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.98M | -23.91M | -13.52M | -3.23M | -9.71M | -31.62M | 7.54M | 44.22M | 75.1M | 136.31M |
| Operating CF Margin % | -42.99% | -33.24% | -14.7% | -2.69% | -8.27% | -14.41% | 2.54% | 12.25% | 16.85% | 26.36% |
| Operating CF Growth % | -3.77% | 14.53% | 43.46% | 76.1% | -200.46% | -225.62% | 123.83% | 486.89% | 69.82% | 81.51% |
| Net Income | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M | 66.35M |
| Depreciation & Amortization | 3.51M | 3.84M | 3.92M | 4.12M | 7.94M | 19.59M | 25.93M | 27.19M | 23.46M | 21.41M |
| Stock-Based Compensation | 6.38M | 6.62M | 5.96M | 9.81M | 12.99M | 22.52M | 26.73M | 33.14M | 36.25M | 43.6M |
| Deferred Taxes | 80K | 12K | 0 | -23K | 0 | -6.26M | 133K | -3.84M | -233K | -581K |
| Other Non-Cash Items | -184K | 2.06M | 251K | 312K | 4.74M | 3.87M | 7.68M | 66.3M | 12.8M | 5.52M |
| Working Capital Changes | -6.41M | -5.44M | -651K | -4.85M | -481K | 4.22M | -16.38M | -4.16M | -21.32M | 0 |
| Change in Receivables | -5.32M | -3.96M | -452K | -6.16M | 955K | -8.57M | -4.5M | 3.89M | -6.41M | -708K |
| Change in Inventory | 292K | -1.85M | 1.92M | -3.4M | 1.06M | -1.46M | -3.01M | -1.69M | -5.87M | -2.86M |
| Change in Payables | -1.44M | 1.73M | -1.57M | -141K | 711K | 5.16M | 152K | -134K | -4.3M | -1.04M |
| Cash from Investing | -4.21M | -1.2M | -1.87M | -42.73M | -3.84M | -739.21M | -29.39M | 15.11M | -56.27M | -9.21M |
| Capital Expenditures | -4.21M | -1.75M | -1.87M | -2.76M | -2.84M | -5.38M | -8.55M | -9.96M | -11.29M | -9.68M |
| CapEx % of Revenue | 6.47% | 2.44% | 2.04% | 2.29% | 2.41% | 2.45% | 2.88% | 2.76% | 2.53% | 1.87% |
| Acquisitions | 0 | 440K | 0 | -40M | 0 | -736.83M | 0 | 0 | 5.01M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -2K | 560K | 0 | 23K | 0 | -162.42M | 0 | 0 | 0 | -2.85M |
| Cash from Financing | 52.33M | -218K | 59.5M | 127.29M | 203.59M | 596.32M | 3.49M | 2.84M | 4.9M | -4.22M |
| Debt Issued (Net) | 19.16M | -2.31M | -292K | -25.21M | -100K | 0 | -1.28M | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 200K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.22M | 1.9M | 4.75M | 14.65M | 9.86M | 2.5M | 4.78M | 2.84M | -15.09M | -4.22M |
| Net Change in Cash | 20.14M | -25.33M | 44.1M | 81.32M | 190.05M | -176.02M | -18.95M | 62.33M | 23.3M | 123.59M |
| Free Cash Flow | -32.19M | -25.67M | -15.39M | -5.99M | -12.55M | -37M | -1.01M | 34.26M | 63.81M | 126.63M |
| FCF Margin % | -49.46% | -35.68% | -16.73% | -4.97% | -10.68% | -16.85% | -0.34% | 9.49% | 14.31% | 24.49% |
| FCF Growth % | 2.83% | 20.26% | 40.03% | 61.1% | -109.55% | -194.84% | 97.26% | 3478.8% | 86.24% | 98.45% |
| FCF per Share | -1.12 | -0.76 | -0.42 | -0.13 | -0.24 | -0.54 | -0.01 | 0.47 | 0.82 | 1.57 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x | 2.05x |
| Interest Paid | 2.15M | 2.72M | 1.55M | 332K | 13K | 9K | 9K | 0 | 0 | 0 |
| Taxes Paid | 7K | 21K | 79K | 35K | 112K | 112K | 570K | 1.7M | 2.24M | 0 |
Key Ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -56.59% | -64.05% | -39.32% | -7.89% | -10.57% | -9.96% | -3.37% | -7.02% | 2.17% | 5.34% |
| Return on Invested Capital (ROIC) | -100.3% | -73.1% | -59.96% | -18.79% | -29.83% | -11.97% | -3.28% | -7.25% | 1.32% | 4.39% |
| Gross Margin | 60.88% | 60.81% | 64.05% | 69.66% | 64.71% | 66.11% | 65.74% | 68.73% | 66.88% | 70.1% |
| Net Margin | -48.18% | -43.09% | -25% | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | 5.42% | 12.83% |
| Debt / Equity | 0.43x | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x | 0.03x |
| Interest Coverage | -10.45x | -5.37x | -11.33x | -22.34x | -154.54x | -339.85x | -207.48x | -5719.67x | 8071.00x | - |
| FCF Conversion | 0.89x | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x | 2.05x |
| Revenue Growth | 31.48% | 10.55% | 27.87% | 30.82% | -2.4% | 86.85% | 35.09% | 21.76% | 23.46% | 16.01% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics